News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cerus Corporation (CERS) Release: Partnership To Initiate Development Of Whole Blood Pathogen Inactivation For Sub-Saharan Africa


3/26/2014 9:21:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ: CERS) announced today that the Humanitarian Foundation Swiss Red Cross has granted funds to Swiss Tranfusion SRC (Blutspende SRK Schweiz) to adapt the INTERCEPT Blood System for red blood cells for pathogen inactivation and transfusion of whole blood, specifically for sub-Saharan African countries. The initial funding of 1.5 million Swiss Francs will support the feasibility phase of the project and completion of in vitro studies to support patient clinical trials.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES